A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.12.11.20238410: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The clinical study received ethical approval from WCG Institutional Review Board and all participants provided informed consent (NCT 04557046 clinicaltrials.gov).
Consent: Nasal swab samples were provided by a commercial supplier (MRN Diagnostics, Florida, USA), and also collected from an at-risk population (LumiraDx Stirling, UK), under approved protocols and informed consent.Randomization not detected. Blinding They were subsequently retested in a blinded manner. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. …
SciScore for 10.1101/2020.12.11.20238410: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The clinical study received ethical approval from WCG Institutional Review Board and all participants provided informed consent (NCT 04557046 clinicaltrials.gov).
Consent: Nasal swab samples were provided by a commercial supplier (MRN Diagnostics, Florida, USA), and also collected from an at-risk population (LumiraDx Stirling, UK), under approved protocols and informed consent.Randomization not detected. Blinding They were subsequently retested in a blinded manner. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04557046 Recruiting Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag … Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
